Could a Two-Vaccine strategy better shield spleenless patients from pneumonia?
NCT ID NCT03873727
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This trial investigates whether giving two different pneumonia vaccines—one followed by another a year later—boosts immune protection more than a single vaccine alone in adults who have had their spleen removed. People without a spleen are at higher risk for serious pneumococcal infections. The study compares a combined vaccine approach against the standard single vaccine, measuring antibody responses in blood samples.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Prevenar13 (PCV13) and Pneumovax (PPS23) vaccines
What this could lead to
If successful, this could establish a more effective revaccination schedule to better protect splenectomised patients from serious pneumococcal infections.
What could go wrong
This is a Phase 2 trial with only 39 participants, so results may not apply to all patients. The immune response measured may not translate to real-world infection prevention.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPLENECTOMISED PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIC 1417 Cochin-Pasteur - GH Broca-Cochin-Hôtel-Dieu
Paris, 75014, France